PMC:7200337 / 110769-113370 JSONTXT

Annnotations TAB JSON ListView MergeView

2_test

Id Subject Object Predicate Lexical cue
32505227-29242543-46575472 1230-1234 29242543 denotes 2018
32505227-32273594-46575473 1454-1458 32273594 denotes 2020
32505227-32092539-46575474 1467-1471 32092539 denotes 2020
32505227-32273591-46575475 1982-1986 32273591 denotes 2020
T10568 1230-1234 29242543 denotes 2018
T15705 1454-1458 32273594 denotes 2020
T77217 1467-1471 32092539 denotes 2020
T35247 1982-1986 32273591 denotes 2020

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T60 1054-1058 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T61 1296-1304 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T103 1724-1729 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T632 68-76 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T633 79-88 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T634 250-258 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T635 394-402 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T636 495-503 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T637 816-824 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T638 969-977 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T639 1330-1338 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T640 1402-1410 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T641 2038-2046 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T642 2445-2453 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T121 39-40 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T122 89-92 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T123 181-188 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T124 349-350 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T125 425-428 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T126 511-512 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T127 529-530 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T128 1230-1234 http://purl.obolibrary.org/obo/CLO_0001185 denotes 2018
T129 1367-1373 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal
T130 1679-1680 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T131 1937-1938 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T132 2111-2118 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T133 2339-2340 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T134 2494-2499 http://purl.obolibrary.org/obo/CLO_0001658 denotes ACTIV

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T4566 1858-1862 Chemical denotes cGMP http://purl.obolibrary.org/obo/CHEBI_16356

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T11 1186-1191 http://purl.obolibrary.org/obo/GO_0007568 denotes aging
T12 1577-1593 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3640 2575-2577 Gene denotes to Gene:6999
3641 2513-2515 Gene denotes to Gene:6999
3642 2249-2251 Gene denotes to Gene:6999
3643 2173-2175 Gene denotes to Gene:6999
3644 2094-2096 Gene denotes to Gene:6999
3645 2082-2084 Gene denotes to Gene:6999
3646 1998-2000 Gene denotes to Gene:6999
3647 1934-1936 Gene denotes to Gene:6999
3648 1810-1812 Gene denotes to Gene:6999
3649 1075-1077 Gene denotes to Gene:6999
3650 865-867 Gene denotes to Gene:6999
3651 786-788 Gene denotes to Gene:6999
3652 770-772 Gene denotes to Gene:6999
3653 662-664 Gene denotes to Gene:6999
3654 49-51 Gene denotes to Gene:6999
3655 250-258 Species denotes SARS-CoV Tax:694009
3656 323-331 Species denotes MERS-CoV Tax:1335626
3657 394-404 Species denotes SARS-CoV-2 Tax:2697049
3658 1411-1419 Species denotes patients Tax:9606
3659 2325-2333 Species denotes patients Tax:9606
3660 2398-2410 Species denotes participants Tax:9606
3661 1858-1862 Chemical denotes cGMP
3662 68-88 Disease denotes SARS-CoV-2 infection MESH:C000657245
3663 495-503 Disease denotes COVID-19 MESH:C000657245
3664 816-824 Disease denotes COVID-19 MESH:C000657245
3665 969-977 Disease denotes COVID-19 MESH:C000657245
3666 1330-1338 Disease denotes COVID-19 MESH:C000657245
3667 1402-1410 Disease denotes COVID-19 MESH:C000657245
3668 2038-2046 Disease denotes COVID-19 MESH:C000657245
3669 2445-2453 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T660 0-10 Sentence denotes Challenges
T661 11-216 Sentence denotes Although the development of a vaccine to protect against SARS-CoV-2 infection has progressed at an unprecedented rate and produced an impressive volume of candidates for testing, many challenges lie ahead.
T662 217-522 Sentence denotes The prior knowledge gained after SARS-CoV-1 was first discovered in 2003, and the subsequent emergence of MERS-CoV in 2012 provided a significant jumpstart, but the progress of SARS-CoV-2 vaccine development has already far outstripped the point of the blueprint created before COVID-19 became a pandemic.
T663 523-720 Sentence denotes While a variety of platforms are simultaneously being innovated or adapted, they each have strengths and limitations, many of which relate to the delicate balance between safety and immunogenicity.
T664 721-881 Sentence denotes Many shortcuts have been taken and will continue to be taken due to the urgency of the ongoing COVID-19 pandemic, but significant concerns need to be addressed.
T665 882-1023 Sentence denotes One such concern involves the accumulating data supporting the initial assessment that COVID-19 is disproportionately severe in older adults.
T666 1024-1236 Sentence denotes In conjunction with the large body of work related to immune senescence, these findings indicate that vaccine design should take into consideration the impact of aging on vaccine efficacy (Nikolich-Žugich, 2018).
T667 1237-1514 Sentence denotes Furthermore, questions remain regarding the possibility of antibody-dependent enhancement of COVID-19, with in vitro experiments, animal studies, and two studies of COVID-19 patients supporting this possibility (Cao, 2020, Tetro, 2020, Zhang et al., 2020a, Zhao et al., 2020a).
T668 1515-1689 Sentence denotes Assuming vaccine candidates that can safely induce protective immune responses are identified, additional major hurdles will be the production and dissemination of a vaccine.
T669 1690-1988 Sentence denotes For some types of vaccines, large-scale production will not be as much of an issue, and infrastructure already in place to produce current Good Manufacturing Practice (cGMP)-quality biologics can be repurposed, but this will only be applicable to a subset of the candidates (Thanh Le et al., 2020).
T670 1989-2411 Sentence denotes In order to address the urgent need and stem the COVID-19 pandemic, regulatory agencies need to continue to support rapid testing and progression of vaccine candidates, companies need to disseminate important findings directly and openly, and researchers need to investigate correlates of protection using in-depth immune monitoring of patients with a broad range of clinical presentations and clinical trial participants.
T671 2412-2601 Sentence denotes The newly announced Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is designed to bring together numerous governmental and industry entities to help address this need.